Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin beta receptor signaling
eLife · 2023
DOI: 10.7554/elife.83533 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Xing Feng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunobiology and Yale Stem Cell Center, Yale University School of Medicine, New Haven, United States. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Mesenchymal Stem Cells. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Acute lymphoblastic and myeloblastic leukemias (ALL and AML) have been known to modify the bone marrow microenvironment and disrupt non-malignant hematopoiesis. However, the molecular mechanisms driving these alterations remain poorly defined. Using mouse models of ALL and AML, here we show that leukemic cells turn off lymphopoiesis and erythropoiesis shortly after colonizing the bone marrow. ALL and AML cells express lymphotoxin α1β2 and activate lymphotoxin beta receptor (LTβR) signaling in mesenchymal stem cells (MSCs), which turns off IL7 production and prevents non-malignant lymphopoiesis. We show that the DNA damage response pathway and CXCR4 signaling promote lymphotoxin α1β2 expression in leukemic cells. Genetic or pharmacological disruption of LTβR signaling in MSCs restores lymphopoiesis but not erythropoiesis, reduces leukemic cell growth, and significantly extends the survival of transplant recipients. Similarly, CXCR4 blocking also prevents leukemia-induced IL7 downregulation and inhibits leukemia growth. These studies demonstrate that acute leukemias exploit physiological mechanisms governing hematopoietic output as a strategy for gaining competitive advantage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunobiology and Yale Stem Cell Center, Yale University School of Medicine, New Haven, United States.
- Center of Molecular and Cellular Oncology and Department of Immunobiology, Yale University, New Haven, United States.
- Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea.
- Department of Cell Biology and Yale Stem Cell Center, Yale University, New Haven, United States.
- Department of Laboratory Medicine, University of California, San Francisco, San Francisco, United States.
- Department of Genetics, School of Medicine, Yale University, New Haven, United States.
ORCID-Profile: Xing Feng, Xinyue Chen, Shangqin Guo, Jungmin Choi, Joao Pedro Pereira
Förderung
- NIH HHS
- NIAID NIH HHS
- NCI NIH HHS
- NIDDK NIH HHS
- National Institutes of Health
Zitieren
APA
Feng, X., Sun, R., Lee, M., Chen, X., Guo, S., Geng, H., Müschen, M., Choi, J., & Pereira, J. P. (2023). Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin beta receptor signaling. eLife. https://doi.org/10.7554/elife.83533
Vancouver
Feng X, Sun R, Lee M, Chen X, Guo S, Geng H, et al. Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin beta receptor signaling. eLife. 2023. doi:10.7554/elife.83533
BibTeX
@article{Feng2023,
author = {Feng, Xing and Sun, Ruifeng and Lee, Moonyoung and Chen, Xinyue and Guo, Shangqin and Geng, Huimin and Müschen, Marcus and Choi, Jungmin and Pereira, Joao Pedro},
title = {Cell circuits between leukemic cells and mesenchymal stem cells block lymphopoiesis by activating lymphotoxin beta receptor signaling},
journal = {eLife},
year = {2023},
doi = {10.7554/elife.83533}
}
EUVIMED